Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Serial olfactory testing for the diagnosis of prodromal Parkinson disease in the Parkinson Associated Risk Syndrome (PARS) study
Movement Disorders
S16 - Movement Disorders: PD Biomarkers and Clinical Trials (3:54 PM-4:06 PM)
003

Olfactory testing has been proposed as a screening tool for the diagnosis of PD due to its low cost and ease of completion. Hyposmia is sensitive for the development of PD, but lacks specificity. We assess whether repeat smell testing improves its diagnostic characteristics for predicting conversion to PD in a community cohort.

To assess whether repeat olfactory testing in initially hyposmic subjects improves prediction of conversion to Parkinson disease (PD).

Participants completed up to 12 years of clinical and imaging evaluations as part of PARS. Olfaction was assessed with the University of Pennsylvania Smell Identification Test (UPSIT), where accuracy less than the 15th percentile of age and gender norms was considered hyposmic.  Development of PD was defined as clinical diagnosis on annual assessments or DAT deficit (less than 65% of age-expected lowest putamen specific binding ratio) on [123I] β-CIT SPECT scans completed approximately every two years. Kaplan Meier survival analysis and Cox proportional hazards regression were used to estimate the hazard ratio for developing PD based on olfactory testing.

Of 155 participants who were hyposmic at baseline, 46 (30%) reverted to normosmia. None of 88 initially normosmic subjects and only 1 of 46 (2%) of reverters developed evidence of PD, compared to 23 of 109 (21%) subjects with consistent hyposmia. Consistent hyposmia had sensitivity of 96% and specificity of 61% for the development of clinical or imaging evidence of PD, compared to 100% and 40%, respectively, for hyposmia on a single, initial test.  In Cox models accounting for potential confounding factors, the hazard ratio for developing PD between consistent hyposmia and reversion was 10.2 (95% CI: 1.3-77.2, p=0.03). 

Serial smell testing improves detection of prodromal PD compared to a single test. Repeat testing may be a cost-effective strategy to identify at-risk patients for early diagnosis and disease modification studies.

Authors/Disclosures
Pavan Vaswani, MD (Parkinson’s Disease and Movement Disorders Center / University of Pennsylvania)
PRESENTER
Dr. Vaswani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Vaswani has received personal compensation in the range of $500-$4,999 for serving as a Travel/training support with Medtronic.
James F. Morley, MD, PhD Dr. Morley has nothing to disclose.
Danna L. Jennings, MD (Denali Therapeutics) Dr. Jennings has received personal compensation for serving as an employee of Denali Therapeutics . Dr. Jennings has received stock or an ownership interest from Denali Therapeutics.
Andrew D. Siderowf, MD Dr. Siderowf has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boehringer-Ingelheim. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for askbio. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for capsida. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Prilenia. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Wave. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurogastrix. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Prevail. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alerity. Dr. Siderowf has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Clintrex. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Inhibikase.
Kenneth L. Marek, MD (IND) Dr. Marek has received personal compensation for serving as an employee of IND. Dr. Marek has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for invicro. Dr. Marek has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Marek has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Marek has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biohaven. Dr. Marek has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for takeda. Dr. Marek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Denali. Dr. Marek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Koneksa. Dr. Marek has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Xingimaging. Dr. Marek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neuron23. Dr. Marek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Marek has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Marek has received research support from Michael J Fox Foundation.